Research programme: antibody therapeutics - TNAX Biopharma Corporation
Latest Information Update: 10 Jun 2024
At a glance
- Originator TNAX Biopharma Corporation
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 27 May 2024 Early research in Unspecified in Japan (Parenteral) prior to May 2024 (TNAX Biopharma Corporation pipeline, May 2024)